1. Home
  2. SKT vs TMDX Comparison

SKT vs TMDX Comparison

Compare SKT & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SKT

Tanger Inc.

HOLD

Current Price

$32.58

Market Cap

3.9B

Sector

Real Estate

ML Signal

HOLD

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$136.73

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKT
TMDX
Founded
1981
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.2B
IPO Year
1993
2019

Fundamental Metrics

Financial Performance
Metric
SKT
TMDX
Price
$32.58
$136.73
Analyst Decision
Buy
Buy
Analyst Count
7
8
Target Price
$36.14
$144.25
AVG Volume (30 Days)
921.5K
657.5K
Earning Date
02-24-2026
02-26-2026
Dividend Yield
3.59%
N/A
EPS Growth
8.00
170.70
EPS
0.94
2.54
Revenue
$575,140,000.00
$566,354,000.00
Revenue This Year
$3.57
$38.73
Revenue Next Year
$4.70
$20.55
P/E Ratio
$34.64
$53.35
Revenue Growth
10.01
41.20
52 Week Low
$28.69
$58.54
52 Week High
$36.76
$156.00

Technical Indicators

Market Signals
Indicator
SKT
TMDX
Relative Strength Index (RSI) 36.81 53.96
Support Level $33.30 $132.02
Resistance Level $33.70 $149.22
Average True Range (ATR) 0.73 7.66
MACD -0.15 0.20
Stochastic Oscillator 14.55 48.91

Price Performance

Historical Comparison
SKT
TMDX

About SKT Tanger Inc.

Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: